Loading…
New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin
Dalbavancin, oritavancin and telavancin are semisynthetic lipoglycopeptides that demonstrate promise for the treatment of patients with infections caused by multi-drug-resistant Gram-positive pathogens. Each of these agents contains a heptapeptide core, common to all glycopeptides, which enables the...
Saved in:
Published in: | Drugs (New York, N.Y.) N.Y.), 2010-05, Vol.70 (7), p.859-886 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Dalbavancin, oritavancin and telavancin are semisynthetic lipoglycopeptides that demonstrate promise for the treatment of patients with infections caused by multi-drug-resistant Gram-positive pathogens. Each of these agents contains a heptapeptide core, common to all glycopeptides, which enables them to inhibit transglycosylation and transpeptidation (cell wall synthesis). Modifications to the heptapeptide core result in different
in vitro
activities for the three semisynthetic lipoglycopeptides. All three lipoglycopeptides contain lipophilic side chains, which prolong their half-life, help to anchor the agents to the cell membrane and increase their activity against Gram-positive cocci. In addition to inhibiting cell wall synthesis, telavancin and oritavancin are also able to disrupt bacterial membrane integrity and increase membrane permeability; oritavancin also inhibits RNA synthesis. Enterococci exhibiting the VanA phenotype (resistance to both vancomycin and teicoplanin) are resistant to both dalbavancin and telavancin, while oritavancin retains activity. Dalbavancin, oritavancin and telavancin exhibit activity against VanB vancomycin-resistant enterococci. All three lipoglycopeptides demonstrate potent
in vitro
activity against
Staphylococcus aureus
and
Staphylococcus epidermidis
regardless of their susceptibility to meticillin, as well as
Streptococcus
spp. Both dalbavancin and telavancin are active against vancomycin-intermediate
S. aureus
(VISA), but display poor activity versus vancomycin-resistant
S. aureus
(VRSA). Oritavancin is active against both VISA and VRSA. Telavancin displays greater activity against
Clostridium
spp. than dalbavancin, oritavancin or vancomycin.
The half-life of dalbavancin ranges from 147 to 258 hours, which allows for once-weekly dosing, the half-life of oritavancin of 393 hours may allow for one dose per treatment course, while telavancin requires daily administration. Dalbavancin and telavancin exhibit concentration-dependent activity and AUC/MIC (area under the concentration-time curve to minimum inhibitory concentration ratio) is the pharmacodynamic parameter that best describes their activities. Oritavancin’s activity is also considered concentration-dependent
in vitro
, while
in vivo
its activity has been described by both concentration and time-dependent models; however, AUC/MIC is the pharmacodynamic parameter that best describes its activity.
Clinical trials involving patients with complicated skin and skin st |
---|---|
ISSN: | 0012-6667 1179-1950 |
DOI: | 10.2165/11534440-000000000-00000 |